AnaptysBio (NASDAQ:ANAB) Stock Price Up 16.5% – What’s Next?

AnaptysBio, Inc. (NASDAQ:ANAB) rose 16.5% on Thursday . The stock traded as high as $18.82 and last traded at $18.81. Approximately 533,624 shares were traded during trading, a decline of 53% from the average daily volume of 1,131,849 shares. The stock had previously closed at $16.15.

Analysts Set New Price Targets

ANAB has been the subject of several recent analyst reports. Guggenheim dropped their price objective on shares of AnaptysBio from $90.00 to $36.00 and set a “buy” rating for the company in a report on Thursday, December 12th. BTIG Research lowered AnaptysBio from a “buy” rating to a “neutral” rating in a research note on Monday, December 2nd. Wedbush reiterated an “outperform” rating and issued a $40.00 price objective on shares of AnaptysBio in a research report on Wednesday. Truist Financial lowered their price objective on AnaptysBio from $30.00 to $20.00 and set a “hold” rating for the company in a research report on Wednesday, December 18th. Finally, Wells Fargo & Company lowered their price objective on AnaptysBio from $56.00 to $40.00 and set an “overweight” rating for the company in a research report on Thursday, December 12th. Four equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, AnaptysBio currently has a consensus rating of “Moderate Buy” and an average price target of $40.08.

AnaptysBio Stock Performance

The company has a 50-day moving average of $15.91 and a 200-day moving average of $25.91. The firm has a market capitalization of $558.91 million and a price-to-earnings ratio of -3.03.

Insider Activity at AnaptysBio

In other news, Director Ecor1 Capital, Llc bought 6,646 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were purchased at an average price of $12.95 per share, for a total transaction of $86,065.70. Following the purchase, the director now owns 7,880,094 shares of the company’s stock, valued at approximately $102,047,217.30. The trade was a 0.08 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 33.70% of the stock is owned by insiders.

Institutional Investors Weigh In On AnaptysBio

Several institutional investors have recently bought and sold shares of the company. FMR LLC lifted its stake in AnaptysBio by 15.3% in the 3rd quarter. FMR LLC now owns 3,309,175 shares of the biotechnology company’s stock valued at $110,857,000 after acquiring an additional 438,557 shares in the last quarter. Frazier Life Sciences Management L.P. lifted its stake in AnaptysBio by 2.0% in the 3rd quarter. Frazier Life Sciences Management L.P. now owns 2,209,189 shares of the biotechnology company’s stock valued at $74,008,000 after acquiring an additional 43,598 shares in the last quarter. Vanguard Group Inc. lifted its stake in AnaptysBio by 8.4% in the 4th quarter. Vanguard Group Inc. now owns 1,843,740 shares of the biotechnology company’s stock valued at $24,411,000 after acquiring an additional 143,584 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of AnaptysBio by 4.6% during the 4th quarter. Geode Capital Management LLC now owns 486,597 shares of the biotechnology company’s stock worth $6,444,000 after purchasing an additional 21,196 shares in the last quarter. Finally, Assenagon Asset Management S.A. raised its stake in shares of AnaptysBio by 55.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock worth $15,927,000 after purchasing an additional 168,813 shares in the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.